soul trial oral semaglutide cardiovascular outcomes nejm 2025 results The Role of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Cardiovascular-Kidney-Metabolic Syndrome Semaglutide and Cardiovascular Outcomes in

Semaglutide is a long-acting glucagon like peptide agonist developed by Novo Nordisk and approved by Food and Drug Administration for the treatment of type -2 diabetes

Most commercial and Medicare Part D plans from Aetna list Jardiance as a preferred brand drug

reading time: 7 minutes 2 Likes JLC November 29, 2025, 4:33pm 3 Read an article the other day about people trying to get off GLP-1s

IS significantly increased the levels of reactive oxygen species (ROS) and malondialdehyde (MDA), while inhibiting antioxidant defense mechanisms such as superoxide dismutase (SOD) and glutathione (GSH), which is consistent with oxidative stress as a key driver of chronic kidney disease (CKD) progression ( To further investigate the signaling mechanisms underlying AST-mediated protection in CKD, we focused on the Nrf2/HO-1 pathway, a central regulator of cellular antioxidant defense

This information allows our physicians to confirm if stem cell therapy is a genuinely promising option for you and, if so, to design a treatment plan that is precise and truly personalized